Regulatory Roche, Eli Lilly get FDA nod for new Alzheimer’s blood test BioPharma DiveLabcorp and Quest Diagnostics both plan to offer the test, which secured CE mark certification earlier this year.NeuroscienceRead full story pharminent August 25, 2026 (Last updated: August 26, 2026) BioPharma Dive Labcorp and Quest Diagnostics both plan to offer the test, which secured CE mark certification earlier this year. Neuroscience Read full story Post navigation Previous: China’s Haisco forms immunology biotech with up to $1.5B from American VCsNext: FDA Approves J&J’s Imaavy for Warm Autoimmune Hemolytic Anemia, the First Therapy Ever Cleared in the Disease Related Stories Regulatory Jazz secures FDA approval for Ziihera in advanced HER2+ GEA pharminent August 26, 2026 Regulatory Expanded US Imaavy approval first ever for wAIHA pharminent August 25, 2026 Regulatory FDA greenlights Roche’s biomarker blood test for Alzheimer’s pharminent August 25, 2026
